Coronavirus disease 2019 (COVID-19) outbreak on an in-patient medical unit associated with unrecognized exposures in common areas—Epidemiological and whole-genome sequencing investigation
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
In-depth characterization of intratumoral heterogeneity in refractory B-cell non-Hodgkin lymphoma through the lens of a Research Autopsy Program
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Molecular and Pathology Features of Colorectal Tumors and Patient Outcomes Are Associated with Fusobacterium nucleatum and Its Subspecies animalis
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Early signatures of breast cancer up to seven years prior to clinical diagnosis in plasma cell-free DNA methylomes
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
DNA Methylation-Based Classification of Small B-Cell Lymphomas: A Proof-of-Principle Study
Home » Archives for Helena Nunes » Page 2
Categories
Categories
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Top Posts
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
- Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression